Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT05517811
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Accepted

Interventions

  • TEG indices — DIAGNOSTIC_TEST
    Blood samples

Study Details

The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.

Key Dates

Start date
Jun 26, 2022
Status verified
Jan 2025
Primary completion
May 31, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
400 participants (estimated)

Arms

  • Arm: Cancer
    new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma
  • Arm: Control
    Patients undergoing major surgery

Primary Outcome Measure

TEG indices of coagulation [ Time Frame: One Year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado DenverAuroraColorado80045
Tracey MacDermott, BA BS CCRC
[email protected]
303-724-2757
Ivan Rodriguez, MD
[email protected]
Ana Fleisner, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Aurora, CO

By condition
Colorectal cancerEsophageal cancerLiver cancerLung cancer
By specialty
OncologyGI oncologyHepatologyLung oncologyLung disease
By research site
University of Colorado Denver· Aurora, CO

Related Studies